DAX23.702 -0,2%ESt505.490 -0,3%Top 10 Crypto15,63 -1,7%Dow46.316 +0,2%Nas22.591 +0,5%Bitcoin96.695 -0,8%Euro1,1749 +0,2%Öl67,13 -0,8%Gold3.830 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 DroneShield A2DMAA RENK RENK73 Lufthansa 823212 NVIDIA 918422 HENSOLDT HAG000 Novo Nordisk A3EU6F Tesla A1CX3T Siemens Energy ENER6Y Alibaba A117ME BYD A0M4W9 Deutsche Telekom 555750 Mercedes-Benz Group (ex Daimler) 710000 Commerzbank CBK100 SAP 716460
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Shutdown droht: DAX leichter -- Asiens Börsen uneins -- Lufthansa-Piloten vor Urabstimmung -- Continental sieht Chance auf DAX-Verbleib trotz Abspaltung -- Rüstungsaktien, Etsy, Wolfspeed im Fokus
Top News
Verbraucher aufgepasst - Neuerungen und Gesetze: Das ändert sich ab Oktober 2025 Verbraucher aufgepasst - Neuerungen und Gesetze: Das ändert sich ab Oktober 2025
Vor drohendem US-Shutdown: Wieso DAX-Anleger so zurückhaltend agieren Vor drohendem US-Shutdown: Wieso DAX-Anleger so zurückhaltend agieren
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Teva Pharmaceutical Industries Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
16,25 EUR +0,50 EUR +3,17 %
STU
19,24 USD +0,90 USD +4,91 %
nachbörslich
BTT
Teva Pharmaceutical Industries jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone
Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN883035

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS8816242098

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTEVA

Teva Pharmaceutical Industries Aktien News

DatumMeistgelesen
BenzingaIs Teva Pharmaceutical Indus Gaining or Losing Market Support?
ZacksAlvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
ZacksTEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
Wer­bungTeva Pharmaceutical Industries-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BenzingaTeva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
GlobesStanley Druckenmiller builds Teva position.
BenzingaHow Is The Market Feeling About Teva Pharmaceutical Indus?
GlobesAnalysts see huge upside in Teva
ZacksTEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
BenzingaTeva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
ZacksCompared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
GlobesTeva again raises profit guidance
BenzingaA Glimpse of Teva Pharmaceutical Indus's Earnings Potential
ZacksCountdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
GlobesIsraeli institutional investors bet on Teva
ZacksTEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
BenzingaLooking Into Teva Pharmaceutical Indus's Recent Short Interest
GlobesTeva launches startup challenge program
BenzingaWhat Analysts Are Saying About Teva Pharmaceutical Indus Stock
ZacksTeva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
ZacksZacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
BenzingaGoldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
BenzingaHow Do Investors Really Feel About Teva Pharmaceutical Indus?
GlobeNewswireTeva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
GlobeNewswireTeva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
GlobeNewswireNew Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
GlobeNewswireTeva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New P
BenzingaTeva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
GlobesTeva gives aggressive guidance for innovative drugs
GlobeNewswireTeva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
BenzingaWhere Teva Pharmaceutical Indus Stands With Analysts
ZacksTEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
GlobeNewswireTeva Celiac Disease Candidate Granted Fast Track Designation by US FDA
GlobeNewswireTeva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
BenzingaWhy Is Teva Stock Trading Higher On Tuesday?
ZacksTEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?
GlobeNewswireTeva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
GlobeNewswireTeva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
GlobeNewswireTeva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
GlobeNewswireFitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
GlobesTeva recycling debt after rating upgrade

Teva Pharmaceutical Industries News

Teva Pharmaceutical Industries News: auf dieser Seite finden Sie alle Teva Pharmaceutical Industries News und Nachrichten zur Teva Pharmaceutical Industries Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Teva Pharmaceutical Industries News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Teva Pharmaceutical Industries News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.